Amara Therapeutics launches Dry Days Health, a virtual clinic for women with urinary incontinence
78 million women in the U.S alone suffer from urinary incontinence
Amara Therapeutics has launched Dry Days Health, a virtual clinic designed to expand access to specialist care for women living with urinary incontinence, one of the most widespread yet under-treated conditions in women’s health. In the U.S alone, Amara estimates 78 million women suffer. The service went live this month in Indiana and Maryland, with national U.S expansion planned for 2026.
The company, which operates from Baltimore, Maryland, and Galway, Ireland, said the new clinic aims to address longstanding barriers that prevent many women from receiving appropriate treatment. Although urinary incontinence affects millions worldwide - and is a major contributor to anxiety and depression among midlife women - fewer than half of those affected ever reach a specialist. Stigma, cost, and a shortage of pelvic and bladder health clinicians continue to limit access, leaving many women to manage symptoms alone or rely on over-the-counter products rather than evidence-based care.
Dry Days Health offers next-day virtual appointments with licensed clinicians, providing personalised treatment plans delivered remotely. According to Amara, the goal is to reduce delays to diagnosis and care while offering a level of privacy that may encourage more women to seek support.
“Urinary incontinence is very common but is not a normal part of aging and women deserve better care,” said Dr Jennifer Bepple, Medical Director of Dry Days Health.
“With Dry Days, we’re combining the accessibility of telemedicine with the precision of digital health to finally close the treatment gap for women’s pelvic and bladder health.”
Alongside clinician appointments, patients receive access to Amara’s app-based pelvic health programme, which includes exercises, educational content and progress-tracking tools. The digital component is intended to help women stay engaged in treatment, an area where adherence has historically been a challenge.
The initial rollout will serve as a testbed for broader growth across the US. Amara said it is developing partnerships with major health systems as part of its 2026 expansion plan.
“Dry Days Health isn’t just improving access to care, it’s redefining how women engage with their health,” said Brendan Staunton, CEO of Amara Therapeutics.
“With Dry Days Health, we’re proving that accessible, high-quality pelvic health care can scale nationally. We’re building a model that makes specialist women’s care intuitive and connected, improving outcomes for patients and efficiency for providers.”
Urinary incontinence remains one of the most overlooked areas of women’s health despite its prevalence and impact on quality of life. The condition affects daily activities from exercise to social engagement, and can significantly limit confidence at work and at home. Women often delay seeking help due to embarrassment, misconceptions about normal ageing, or lack of available clinicians—particularly outside metropolitan areas.
Telehealth models have become increasingly common in women’s health, especially in menopause, maternal care and mental health. But the application of virtual care to pelvic and bladder health has been slower to develop, partly due to the perception that assessment and treatment must take place in person. Amara’s model positions digital therapeutics as an adjunct to clinical care rather than a replacement for it, offering a hybrid approach that the company believes can scale.
Amara Therapeutics develops digital therapeutics and virtual care solutions for pelvic and bladder health conditions, including urinary incontinence and overactive bladder. The company says Dry Days Health is part of its broader mission to redesign how women access and sustain treatment for these conditions.